A consensus meeting was held aimed at attaining a consensus on the role of fluoroquinolones in the management of complicated urinary tract infections (cUTI), particularly in countries with high rates (>20%) of fluoroquinolone-resistant uropathogens. Pharmacokinetic/pharmacodynamic and limited clinical data support the fact that specific fluoroquinolone breakpoints might be needed for UTI. Resistant isolates causing mild to moderate cUTI with relatively low minimum inhibitory concentrations (MICs 16e32 mg/mL) might clinically respond to fluoroquinolone therapy.
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The Taiwan Urinary Tract Infection Consensus Meeting was held on September 18, 2010, in Taipei. A total of 12 infectious-disease specialists from 12 major teaching hospitals located in different parts of Taiwan participated in the meeting. The meeting aimed to attain consensus on the role of fluoroquinolones in the management of UTI, particularly in a country with a high rate (>20%) of fluoroquinolone resistance among uropathogens.
Urinary tract infections are the most frequently occurring bacterial infections in the community and in hospitals. Trimethoprimesulfamethoxazole (SXT) is generally considered to be the drug of choice for the treatment of uncomplicated UTI.
1,2 However, the persistently high rates (>20%) of SXT resistance among urinary Escherichia coli isolates have made this agent unsuitable for empirical treatment of UTI (Fig. 1) .
1e3 Several international guidelines recommend fluoroquinolones as the drugs of choice for empirical treatment of UTI, including catheter-associated UTI. 2,4e7 Levofloxacin 750 mg once daily for 5 days has been shown to be as effective as ciprofloxacin 400 mg (intravenous) or 500 mg (oral) twice daily for 10 days in the treatment of adults with cUTI and acute pyelonephritis, including patients with concurrent bacteremia. 8, 9 However, the rapid emergence of fluoroquinolone-resistant E coli (the most commonly encountered uropathogen) suggests that further use would make fluoroquinolones unreliable for treatment within the near future. 10, 11 Moreover, the widespread use of fluoroquinolones for cUTI or catheterassociated UTI might result in reduced susceptibility of respiratory pathogens to these agents. 1,10e12 Increasing resistance of uropathogens to fluoroquinolones is of clinical concern. Rates of levofloxacin susceptibility of clinical isolates of urinary E coli obtained from 12 major teaching hospitals located in different parts of Taiwan ranged from 70% to 80% (Fig. 2 ). In addition, recent studies have found a rapid increase in levofloxacin resistance among E coli isolates from patients treated in emergency departments and outpatient clinics. 10, 11 Risk factors for infections with levofloxacin-resistant E coli include recent hospitalization and prior levofloxacin use. 1, 10, 11 These risk factors should be considered before initiating empirical treatment with a fluoroquinolone for UTI.
However, the key controversy is that in vitro resistance to fluoroquinolones can always translate into clinical failure in patients with UTI, particularly when higher than regular doses of fluoroquinolones (e.g. 750 mg levofloxacin) are administered. Patients with UTI caused by SXT-resistant pathogens have worse clinical outcomes than those infected with susceptible isolates. 1, 13 Nevertheless, in vitro resistance to SXT translates into clinical failure in approximately 50% of patients with community-acquired UTIs. 1, 13 The MIC breakpoints of trimethoprim or SXT for Enterobacteriaceae and staphylococci provided by the Clinical and Laboratory Standards Institute were categorized only for treating UTIs. 14 Importantly, the Clinical and Laboratory Standards Institute provides a urine-specific breakpoint for some fluoroquinolones (lomefloxacin, ofloxacin, and norfloxacin) but not for ciprofloxacin or levofloxacin for Enterobacteriaceae and Pseudomonas aeruginosa.
14 Although most of the clinical microbiology laboratories determine the susceptibilities of urinary isolates of Enterobacteriaceae to levofloxacin and ciprofloxacin by applying non-urine-specific MIC breakpoints, it does not mean that levofloxacin and ciprofloxacin are not suitable for the treatment of UTIs caused by pathogens with "in vitro resistance" to these two agents.
Previous studies have clearly demonstrated that the mean peak urinary concentrations of levofloxacin (0e1.5 hours) were 347 mg/mL at a dose of 500 mg and 620 mg/mL at a dose of 750 mg.
15e17 High-dose levofloxacin (750 mg) exhibited early and prolonged (8e12 hours) urinary bactericidal activity against levofloxacin-resistant E coli isolates (MIC range, 4e32 mg/mL) in virtually all subjects. 15 Previous studies also found that ciprofloxacin at standard doses or ciprofloxacin XR (1,000 mg) once daily had prolonged bactericidal activity in urine. 18 Some reported clinical cases support those ex vivo findings. Miller et al. 19 reported a case in which ciprofloxacin (500 mg twice daily) was an effective treatment for cystitis because of a ciprofloxacin-resistant strain of E coli (MICs > 4 mg/mL). In a clinical trial of levofloxacin (750 mg once daily) versus ciprofloxacin (500 mg twice daily) for the treatment of acute pyelonephritis, four patients were infected with fluoroquinolone-resistant E coli isolates. 8 Ciprofloxacin was effective at eradicating two of four isolates, and levofloxacin was effective against another isolate. The MIC values of ciprofloxacin were 8 mg/mL and greater than 32 mg/mL, and the MIC value of levofloxacin was 32 mg/mL. 8 Additional susceptibility breakpoints for uropathogens may be warranted for selected fluoroquinolones. 16, 19 The susceptibility concentration (4 mg/mL) in urine for norfloxacin is approximately three times its peak serum level.
14 A similar ratio for 750 mg of levofloxacin would have a susceptibility breakpoint in urine between 16 mg/mL and 32 mg/mL. 16, 20 Ciprofloxacin exhibited a higher MIC 90 (64 mg/mL) compared with levofloxacin, indicating a high rate of resistance of E coli isolates to ciprofloxacin. 20 The greater effect of the AcrAB, MdfA, and NorE efflux pumps on ciprofloxacin compared with that on levofloxacin in E coli might partly contribute to this finding. 21, 22 It is reasonable to consider a 5-day course of levofloxacin or a 10-day course of ciprofloxacindthough other fluoroquinolones may be just as effective but have not been evaluateddfor the treatment of cUTI or acute pyelonephritis if the causative uropathogen is susceptible. 23 Moreover, in geographical areas in which more than 20% of urinary E coli isolates are nonsusceptible to levofloxacin, a high daily dose (750 mg) of levofloxacin might still be useful for the empirical treatment of cUTI caused by E coli isolates with MICs less than 32 mg/mL. The major caveat with this higher susceptibility breakpoint for uropathogens would be in patients who have severe cUTIs or urosepsis with concurrent bacteremia.
In summary, pharmacokinetic/pharmacodynamic data and limited clinical observation indicated that UTI caused by isolates with relatively low MICs (e.g. 16 mg/mL) might respond to fluoroquinolone therapy, and that specific fluoroquinolone breakpoints would be required for UTI.
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